Compare CWCO & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | FBRX |
|---|---|---|
| Founded | 1973 | N/A |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.1M | 487.2M |
| IPO Year | 1997 | 2017 |
| Metric | CWCO | FBRX |
|---|---|---|
| Price | $29.48 | $16.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $40.00 | ★ $67.00 |
| AVG Volume (30 Days) | 82.4K | ★ 205.1K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $132,073,368.00 | $36,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | $130.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.90 | $9.12 |
| 52 Week High | $39.12 | $35.80 |
| Indicator | CWCO | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.80 | 28.04 |
| Support Level | $28.17 | $10.50 |
| Resistance Level | $34.26 | $17.00 |
| Average True Range (ATR) | 0.79 | 1.97 |
| MACD | 0.14 | -0.34 |
| Stochastic Oscillator | 50.20 | 1.82 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.